180 Wealth Advisors LLC Has $252,000 Stock Position in Elanco Animal Health Incorporated (NYSE:ELAN)

180 Wealth Advisors LLC raised its stake in Elanco Animal Health Incorporated (NYSE:ELANFree Report) by 11.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,463 shares of the company’s stock after buying an additional 2,301 shares during the period. 180 Wealth Advisors LLC’s holdings in Elanco Animal Health were worth $252,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in ELAN. Glassman Wealth Services boosted its position in Elanco Animal Health by 444.0% in the second quarter. Glassman Wealth Services now owns 2,644 shares of the company’s stock valued at $27,000 after buying an additional 2,158 shares in the last quarter. Spire Wealth Management acquired a new stake in Elanco Animal Health in the second quarter valued at approximately $30,000. Advisory Services Network LLC boosted its position in Elanco Animal Health by 104.1% in the first quarter. Advisory Services Network LLC now owns 5,204 shares of the company’s stock valued at $49,000 after buying an additional 2,654 shares in the last quarter. Captrust Financial Advisors boosted its position in Elanco Animal Health by 57.0% in the first quarter. Captrust Financial Advisors now owns 2,690 shares of the company’s stock valued at $70,000 after buying an additional 977 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new stake in Elanco Animal Health in the fourth quarter valued at approximately $70,000. Institutional investors and hedge funds own 95.29% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on ELAN. The Goldman Sachs Group increased their price objective on Elanco Animal Health from $10.00 to $12.50 and gave the company a “sell” rating in a report on Wednesday. BNP Paribas began coverage on Elanco Animal Health in a research report on Thursday, December 7th. They set an “outperform” rating and a $18.00 price objective for the company. Piper Sandler raised their price objective on Elanco Animal Health from $11.00 to $12.00 and gave the stock a “neutral” rating in a research report on Monday, November 13th. Morgan Stanley upgraded Elanco Animal Health from an “equal weight” rating to an “overweight” rating and set a $16.00 price objective for the company in a research report on Friday, December 15th. Finally, Jefferies Financial Group began coverage on Elanco Animal Health in a research report on Tuesday, December 19th. They set a “buy” rating and a $17.00 price objective for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $15.64.

View Our Latest Stock Analysis on Elanco Animal Health

Elanco Animal Health Trading Down 2.1 %

Shares of Elanco Animal Health stock opened at $14.81 on Thursday. The company has a debt-to-equity ratio of 0.96, a current ratio of 2.82 and a quick ratio of 1.48. Elanco Animal Health Incorporated has a 52 week low of $7.88 and a 52 week high of $15.94. The stock has a 50 day moving average price of $13.40 and a two-hundred day moving average price of $11.82.

Elanco Animal Health (NYSE:ELANGet Free Report) last announced its earnings results on Tuesday, November 7th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.06. The company had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.04 billion. Elanco Animal Health had a positive return on equity of 6.99% and a negative net margin of 26.18%. Elanco Animal Health’s quarterly revenue was up 3.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.20 earnings per share. Sell-side analysts forecast that Elanco Animal Health Incorporated will post 0.92 earnings per share for the current year.

Elanco Animal Health Profile

(Free Report)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

Featured Articles

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELANFree Report).

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.